Open AccessAmBisome Monotherapy and Combination AmBisome–Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial
Author(s) -
Sakib Burza,
Raman Mahajan,
Shahwar Kazmi,
Alexander Nast,
Deepak Kumar,
Vikash Kumar,
Estrella Lasry,
Amit Harshana,
Alan de Lima Pereira,
Pradeep Das,
Neena Verma,
Vidya Nand Rabi Das,
Chandra Shekhar Lal,
B. B. Rewari,
Vishal Goyal,
Suman Rijal,
Fabiana Alves,
Naresh Gill,
Krishna Pandey
Publication year - 2022
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciac127
Subject(s) - medicine , miltefosine , randomized controlled trial , visceral leishmaniasis , tuberculosis , surgery , gastroenterology , leishmaniasis , immunology , pathology
Visceral leishmaniasis (VL) in patients with human immunodeficiency virus (HIV) presents an increasingly important patient cohort in areas where both infections are endemic. Evidence for treatment is sparce, with no high-quality studies from the Indian subcontinent.